MenoVantage PE 90 vcaps

For many women the transition from pre- to post-menopause can be arduous. Changing hormone levels can lead to increased risk for both heart disease and osteoporosis,^1,2 while inducing uncomfortable shorter term issues such as vasomotor symptoms (hot flushes, night sweats), insomnia, vaginal dryness, mood changes and reduction in libido. Although estrogen replacement therapy (ERT) may reduce some of the aforementioned concerns, the Women’s Health Initiative has shown that ERT use in post-menopausal women is linked to an increased risk of both breast cancer and cardiovascular disease.³ However, phytoestrogens provide a viable alternative to ERT. While they share the basic chemical framework of other steroid hormones, potencies are approximately 1000-fold weaker than that of 17-a estradiol.⁴ It is estimated that more than 300 plants contain compounds with estrogenic activity including those found in MenoVantage PE. These include the herbs black cohosh (Actaea racemosa) and Dong quai (Angelica sinensis) which have been shown clinically to reduce menopausal symptoms.^5,6*

• Standardized herbal extracts*
• Potent phytoestrogens: Angelica sinensis and Actaea racemosa*
• Normalizes LH and FSH through the action of Vitex agnus-castus^7,8*
• Gamma-Oryzanol reduces climacteric symptoms and increases HDL-C^9*
• Hesperidin, a citrus bioflavonoid, helps decrease vasomotor activity along with vitamin C^10*
• Vegetarian capsule*

1. Matthews KA. et al. Menopause and Risk Factors for Coronary Heart Disease. N Engl J Med. 1989; 321:641-646.*
2. Christenson ES, Jiang X, Kagan R, Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecol. 2012;64:181-94.*
3. Grimes DA, Lobo RA. Perspectives on the Women’s Health Initiative Trial of Hormone Replacement Therapy. Obstet Gynecol. 2002;100:1344–53.*
4. Sunita P, Pattanayak SP. Phytoestrogens in postmenopausal indications: A theoretical perspective. Pharmacogn Rev. 2011;5:41-7.*
5. Osmers R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. Obstet Gynecol. 2005;105(5 Pt 1):1074-83.*
6. Kupfersztain C, Rotem C, Fagot R, Kaplan B. The immediate effect of natural plant extract, Angelica sinensis and Matricaria chamomilla (Climex) for the treatment of hot flushes during menopause. A preliminary report. Clin Exp Obstet Gynecol. 2003;30:203-6.*
7. Nasri S, Oryan S, Haeri Rohani A, Amin GH, Yahyavi H. The Effects of Vitex agnus castus L. Extract on Gonadotrophines and Testosterone in Male Mice.Iranian Int. J. Sci. 2004,5:25-30.*
8. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus (Chaste-Tree/Berry) in the treatment of menopause-related complaints. J Altern Complement Med. 2009;15:853-62.*
9. Ishihara M, Ito Y, Nakakita T, Maehama T, Hieda S, Yamamoto K, Ueno N. [Clinical effect of gamma-oryzanol on climacteric disturbance -on serum lipid peroxides (author’s transl)]. [Article in Japanese] Nihon Sanka Fujinka Gakkai Zasshi. 1982;34:243-51.*
10. Smith CJ. Non-hormonal control of vaso-motor flushing in menopausal patients.Chic Med. 1964;67:193-5.*
11. Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann KH. Herb induced liver injury presumably caused by black cohosh: a survey of initially purported cases and herbal quality specifications. Ann Hepatol. 2011;10:249-59.*
12. Duffy C, Perez K, Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin. 2007;57:260-77.*
13. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77:415-26.*
14. Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet. 2012;51:77-104. doi: 10.2165/11597910-000000000-00000.*
15. Dugoua JJ, Seely D, Perri D, Koren G, Mills E. Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation. Can J Clin Pharmacol. 2008;15:e74-*

Dosage

Contraindications

Additional Information